LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET.

The live events and replays of the presentations can be accessed via the Events page of the Company’s website at .

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries: 

Lisa DeFrancesco  

Lexicon Pharmaceuticals, Inc. 



EN
25/11/2025

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in t...

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...

December 10, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in No...

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...

December 5, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Participate in Two Upcoming December Invest...

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceutic...

November 25, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London He...

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST). The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering med...

November 11, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...

November 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch